A Phase 1 trial of the targeted agent BLU-285 demonstrated rapid and durable responses with minimal adverse effects in patients with advanced systemic mastocytosis. The study found that 72% of evaluable patients achieved an overall response, with 100% having disease control.
A new study demonstrates techniques to track genetic changes in multiple myeloma over time using cell-free DNA found in blood. This approach potentially provides a more representative view of the disease throughout the body than traditional bone marrow biopsies.
A study showed that treating younger patients with a combination of chemotherapy and a molecularly targeted drug significantly improves response over traditional chemotherapy alone. The therapy combination resulted in a complete response rate of 37% compared to 20% historically, with ongoing maintenance showing deepened responses.
Novel targeted cancer therapies have been shown to improve progression-free survival, response rate, and quality of life for patients with cutaneous T-cell lymphoma. Mogamulizumab has demonstrated significant clinical activity in clearing malignant T-cells in the blood and lymph nodes.
A landmark clinical trial has shown impressive results for a CAR-T cancer treatment in refractory large B-cell lymphoma patients, achieving complete remission in 42% of cases. However, severe side effects including cytokine release syndrome and neurologic problems were also observed, affecting up to 95% of patients.
A Phase 2 study of axi-cel, a CD19-targeting CAR T cell therapy, reported remarkable improvement in outcomes for patients with relapsed or refractory large B-cell lymphoma. The study showed that 42% of patients remained in remission at 15 months, with complete responses in 54% and measurable responses in 82%.
The Kymriah treatment demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients, with significant durability in responses seen across multiple trials. Durable remission rates were observed among 43% of DLBCL patients in the single-site pilot study and 73% at six months in the global trial.
Researchers from the University of Pennsylvania's Abramson Cancer Center have shown encouraging results in treating multiple myeloma patients with CAR T cell therapy and an experimental monoclonal antibody. The studies targeted the B-Cell Maturation Antigen (BCMA) receptor, which is highly expressed in myeloma cells.
Daily low doses of interleukin-2 (IL-2) have been found to be safe and beneficial for patients with chronic graft-versus-host disease, including significant improvements in pediatric patients. IL-2 therapy boosts the production of inflammation-damping Treg cells, providing a mechanism for promoting tolerance in patients with chronic GVHD.
A new review article challenges current methods for forecasting the persistence of slow-growing species, finding that reproductive success is a more reliable predictor. Researchers argue that conservation planners often get it wrong and suggest alternative tools based on realistic parameters.
Scientists sequenced 186 bone marrow biopsies from patients with smoldering multiple myeloma, identifying mutations more frequent in high-risk patients. The study also found that cell-free DNA sequencing may help monitor patients with myeloma and its precursor conditions.